Details

Autor(en) / Beteiligte

• 劉韋新(Wei-Hsin Liu)
• 劉美瑾(Mei-Ching Liu)
• 余本隆(Ben-Long Yu)
• 鄭鴻鈞(Skye Hung-Chun Cheng)
• 李明媛(Ming-Yuan Li)
• 鍾奇峰(Chi-Feng Chung)
• 王宗德(Tzung-De Wang)
• 洪啟峰(Chi-Feng Hung)

Titel

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer

Ist Teil von

• Journal of cancer research and practice, 2014-09, Vol.1 (2), p.163-171

Ort / Verlag

中華民國癌症醫學會

Erscheinungsjahr

2014

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Abstract Trastuzumab, a humanized monoclonal antibody directed against the external domain of the HER-2 protein, has shown remarkable activity against HER-2 positive breast cancer. Consequently, the use of adjuvant trastuzumab plus chemotherapy in patients with HER2-positive stage breast cancer (stage I to III) has become the standard treatment option. However, the role of trastuzumab in neoadjuvant treatment therapy is still uncertain. An increasing number of clinical trials and inadequate analysis show the benefit of adding trastuzumab to chemotherapy in the neoadjuvant setting. We report a case of HER2-positive locally advanced breast cancer in a patient who received cytotoxic agents concomitant with trastuzumab as neoadjuvant therapy, and also review the published literature. The patient achieved pathological complete response, and remained disease-free for more than 5 years.